Recro Gainesville LLC is a wholly-owned subsidiary of Recro Pharma Inc. and provides solid oral dose manufacturing services with a specialization in extended release and controlled substances.
The company's Gainesville, Georgia-based site was acquired from the pharmaceutical company Alkermes in 2015.
As Outsourcing-Pharma.com previously reported, Recro also gained worldwide rights to Alkermes' Phase III long acting pain drug IV/IM meloxicam in return for potential milestone payments as part of the $50m facility divestiture deal.
The company’s new suite now includes the Fette FE 55 tablet press and a new film coater, the Bohle BTC-100, both of which the company said will enable it to compress single- and bi-layer tablets at commercial speeds.
The contract manufacturing and development organization (CDMO) has also added nearly a dozen scientist to its team.